A retrospective study on tolerability and complications of bacillus Calmette-Gu érin (BCG) instillations for non-muscle-invasive bladder cancer.

CONCLUSIONS: Severe complications were encountered in only <5% of patients. Adverse effects requiring treatment interruption were more likely to happen within the first year of treatment. Interrupting BCG treatment due to adverse effects increased the risk of disease progression and tumor recurrence. PMID: 31074322 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research